SBC Medical Group Holdings Earnings Call Transcripts
Fiscal Year 2026
-
SBC Medical Group is recovering financially and expanding globally, highlighted by a new US partnership with Orange Twist. The group targets significant international growth, aims for 10%-50% clinic expansion, and expects global revenue to exceed 20% in the next 3-5 years.
-
Japan's leading aesthetic medical group is recovering revenue per visit and expanding globally through partnerships, notably with U.S.-based OrangeTwist. M&A remains focused on Japan, with incremental overseas growth and a long-term vision for global leadership.
Fiscal Year 2025
-
Clinic revenue grew 2% year-over-year to $1,163 million, with Q4 average revenue per customer up 11%. Profitability improved as net income rose 9% and EBITDA margin reached 40.4%. Strategic focus remains on aesthetic dermatology, AI, and global expansion.
-
The group is recovering from restructuring, with a focus on growth in aesthetic medicine, domestic and international expansion, and R&D through acquisitions. Financial performance is rebounding, and 2026 is expected to see 10%-15% growth in clinics, with risks monitored in customer spend and regulation.
-
Management highlighted a return to growth after restructuring, with franchise expansion, international partnerships, and R&D investments driving future performance. Efforts to improve share liquidity and maintain strong financials support a global growth vision.
-
Franchisee clinics and customer base grew, with average spend per customer recovering. Sales and income stabilized after restructuring, and expansion into Thailand and R&D integration with Waku are underway. Capital policy focuses on liquidity and strategic investments.
-
SBC Medical Group Holdings outlined its strategic restructuring, recent clinic expansions, and focus on high-growth medical areas. Despite a revenue decline from restructuring, the company expects growth to resume in the third quarter, supported by global expansion and enhanced capital policies.
-
Clinic network expanded to 259, with revenue down 18% year-over-year due to strategic restructuring and one-time tax effects. High repeat rate and new clinic formats drive future growth, while investments in high-margin segments and international expansion are prioritized.
-
Management outlined a strategy focused on global expansion, diversified services, and a multi-brand approach, supported by strong financials and a robust capital policy. Recent initiatives include pricing reforms, a major acquisition in Singapore, and a share buyback program.
-
Management outlined strong profitability, a multi-brand strategy, and robust growth plans in Japan and internationally, including recent acquisitions and pricing reforms. Capital policy focuses on share buybacks and liquidity, with future growth driven by dermatology, B2B, and overseas expansion.
-
SBC Medical Group outlined its post-NASDAQ growth strategy, emphasizing multi-brand expansion, international acquisitions, and digital transformation. Financial strength supports capital returns and investments, while new pricing and franchise models aim to boost sustainability and shareholder value.
-
The conference detailed steady growth in customer volumes and revenue, strategic pricing and franchise fee revisions, and a robust balance sheet. Expansion is focused on domestic multi-brand clinics, medical tourism, B2B services, and overseas markets, with measures underway to improve stock liquidity.
Fiscal Year 2024
-
FY2024 revenue grew 6% year-over-year to $205 million, with a 15% increase in annual customers and 43 new clinics. ROE declined 4% due to one-time listing expenses, but recovery measures are in place. Expansion is focused on Asia and the U.S., with ongoing capital allocation improvements.